[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rws\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rws":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100554165","the-real-world-study-of-pyrotinib-in-the-treatment-of-advanced-breast-cancer-with-her2-positive-100554165",false,"NCT06495541","The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Pathological or histopathological confirmed HER2 positive cases cannot be surgically advanced or metastasized Patients with sexual breast cancer (HER2 positive is defined as: standard immunohistochemistry (IHC) Detected as 3+or ISH positive);\n3. There is a traceable medical history record during the treatment period;\n4. Voluntarily participate in this study, sign informed consent, have good compliance, and are willing to cooperate Follow up.\n\nExclusion Criteria:\n\n1. Failure to sign informed consent form;\n2. Previous history of other malignant tumors, but cured skin basal cell carcinoma and cervical cancer Excluding cancer;\n3. Difficulty in swallowing, chronic diarrhea, and intestinal obstruction, which can affect medication administration and absorption Various factors;\n4. Pregnant or lactating women, and women of childbearing age who cannot achieve optimal contraception;\n5. Any other circumstances in which the researcher deems the patient unsuitable to participate in this study.","FEMALE","18 Years",{"count":18,"type":19},500,"ESTIMATED","INTERVENTIONAL",[22],"NA","Research object：Planned to receive pyrrolidine for HER2 positive first-line breast cancer patients\n\nResearch purpose:\n\nMain research objectives:\n\nTo observe the efficacy and safety of pyrrolidine in the treatment of HER2 positive advanced first-line breast cancer.\n\nSecondary research objectives:\n\n1. Evaluate the correlation between patient characteristics in the late stage of treatment and specific treatment plans and clinical outcomes Sex (including safety outcomes)\n2. Evaluate whether and how previous anti HER2 therapy affects the efficacy of subsequent pyrrolitinib treatment\n3. To observe the efficacy of pyrrolitinib in patients with brain metastasis of HER2 positive breast cancer\n\nResearch endpoint:\n\nMain research endpoint:\n\nProgression free survival (rwPFS)\n\nSecondary study endpoint:\n\nEfficacy endpoints: objective response rate (rwORR), disease control rate (rwDCR), until treatment failure Time to Flight (TTF), Total Survival (OS), Security",[25,26,27],"Breast Cancer","RWS","Pyrotinib","NOT_YET_RECRUITING","2026-03-18",{"date":31,"type":32},"2026-03-20","ACTUAL",{"date":34,"type":19},"2026-04-01",{"date":36,"type":19},"2028-07-30",{"name":38,"class":39},"Tianjin Medical University Cancer Institute and Hospital","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":46,"minAge":16,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":65},"100553375","a-real-world-study-of-camrelizumab-alone-or-in-combination-with-apatinibchemotherapy-for-advanced-gastric-cancer-100553375","NCT06485271","A Real-world Study of Camrelizumab Alone or in Combination With Apatinib\u002FChemotherapy for Advanced Gastric Cancer","Inclusion Criteria:\n\n1. Age ≥18 years old, both male and female;\n2. patients with advanced gastric cancer diagnosed by pathology or histology and progressed or recurred after 6 months of adjuvant therapy can also be considered for enrollment;\n3. Have at least one measurable lesion on imaging (RECIST 1.1 criteria), the spiral CT or MR target lesion should be ≥10 mm and lymph node ≥15 mm;\n4. The investigator determines that the patient is amenable to treatment with karelizumab or apatinib;\n5. Voluntary enrollment; good compliance and willingness to cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. Previous use of other immunotherapy drugs (e.g. PD-1 monoclonal antibody, PD-L1 monoclonal antibody, CTLA4 monoclonal antibody, etc.);\n3. Prior use of other anti-angiogenic therapeutic agents (e.g., apatinib, etc.);\n4. Patients who, in the judgment of the investigator, are not suitable for inclusion.","ALL","75 Years",{"count":49,"type":19},504,"OBSERVATIONAL","The purpose of this observational study is to evaluate the safety and efficacy of camrelizumab and apatinib in patients with advanced gastric cancer under real-life conditions, particularly in various subgroups of gastric cancer patients, with a view to providing information about the treatment modalities and efficacy of the treatment in real-life gastric cancer patients and to explore the possible predictive biomarkers of prognosis.Patients, who had both decided to be treated with camrelizumab or apatinib prior to enrollment, were entered into one of the following three cohorts at the discretion of the investigator, based on their disease stage and prior treatment",[53,26,54],"Gastric Cancer","PD-1 Immunotherapy","RECRUITING","2024-06-26",{"date":58,"type":32},"2024-07-03",{"date":60,"type":32},"2023-11-01",{"date":62,"type":19},"2026-10",{"name":64,"class":39},"Changzhi People's Hospital Affiliated to Changzhi Medical College",1]